Phase 3 Study of MAP0004 in Adult Migraineurs

• Status: Completed
• Trial end date: 2011-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a randomized, double blind, placebo controlled, parallel group study of MAP0004 in adult migraineurs. Subjects will self administer study drug in the outpatient setting.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Collaborator: MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan

Criteria

Major Inclusion Criteria:

• Male or female between 18 and 65 years of age.

• History of episodic, acute migraine (with or without aura) with onset prior to 50

Major Exclusion Criteria:

• Known allergy or sensitivity or contraindication to study drugs or their formulations

• History of chronic pulmonary disease, coronary artery disease (CAD), liver disease, kidney disease, seizures, stroke, or major psychiatric condition.

• Any condition that, in the opinion of the Investigator, would make the subject unsuitable for study participation